Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stereotaxis Inc.

www.stereotaxis.com

Latest From Stereotaxis Inc.

Acutus Completes $170M Financing To Support AcQMap Commercialization

The deal includes $100m in Series D financing and a $70m credit facility to help Acutus market the AcQMap electrophysiology mapping system along with the associated vascular access devices, AcQCross QX, AcQGuide Flex and AcQGuide Mini.

Cardiovascular Diagnostic Imaging

Acutus Announces Four Deals To Expand Its Reach Into Electrophysiology

Acutus announced a deal to acquire Rhythm Xience, and new strategic partnerships with Peerbridge Health, Cardiac Designs and MedFact, to offer more electrophysiology products that complement its AcQMap multi-electrode electrophysiology mapping catheter system.

Companies Deals

Starts & Stops: CardioFocus Studies HeartLight X3 In Persistent AF; IntraLink Spine Launches Trial Of Low-Back Device In Australia

Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by Meddevicetracker. This edition covers trial announcements from March 4 through March 17, including trial announcements from CardioFocus, Innovative Cardiovascular Solutions, IntraLink-Spine, Geneveve, Acutus, and Stereotaxis.

Starts & Stops Tracking Trials

Device/Diagnostics Quarterly Deal-Making Statistics, Q3 2017

Third-quarter device financing at $2.38 billion – almost half of that amount from CooperSurgical's $1.1 billion bridge loan – was double the Q2 total, while device acquisitions showed a steep decrease at $3.38 billion versus Q2's $33.4 billion. Diagnostics fundraising also was up in the third quarter, reaching $2.4 billion (a 133% increase over Q2) mostly from Thermo Fisher Scientific's $1.5 billion follow-on offering, which accounted for 63% of the total. In line with the previous quarter's $1.7 billion in M&A, Q3 diagnostics acquisitions had an aggregate value of $1.8 billion, led by Konica Minolta's $1 billion buy of Ambry Genetics.

Medical Device In Vitro Diagnostics
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Stereotaxis Inc.
  • Senior Management
  • Michael P Kaminski, CEO
    Samel W Duggan, II, CFO
    Frank J Cheng, SVP, Mktg. & Bus. Dev.
  • Contact Info
  • Stereotaxis Inc.
    Phone: 314615100
    4320 Forest Park Ave.
    Ste. 100
    St. Louis, MO 63108
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register